# **PRODUCT** INFORMATION



Cabotegravir-d<sub>5</sub>

Item No. 31319

CAS Registry No.:	2750534-77-9	
Formal Name:	(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-	
	hexahydro-6-hydroxy-3-methyl-d <sub>3</sub> -5,7-dioxo-oxazolo[3,2-a] pyrido[1,2-d]pyrazine-2,2-d <sub>2</sub> -8-carboxamide	н
MF:	$C_{19}H_{12}D_5F_2N_3O_5$	
FW:	410.4	
Chemical Purity:	≥98% (Cabotegravir)	
Deuterium		
Incorporation:	≥99% deuterated forms (d₁-d₅); ≤1% d₀	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

# Laboratory Procedures

Cabotegravir-d<sub>5</sub> is intended for use as an internal standard for the quantification of cabotegravir (Item No. 27215) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Cabotegravir-d<sub>5</sub> is supplied as a solid. A stock solution may be made by dissolving the cabotegravir-d<sub>5</sub> in the solvent of choice, which should be purged with an inert gas. Cabotegravir-d<sub>5</sub> is soluble in methanol and DMSO.

# Description

Cabotegravir is an inhibitor of HIV-1 integrase (IC<sub>50</sub> = 3 nM in a strand transfer assay).<sup>1</sup> It inhibits HIV replication in MT-4 cells and peripheral blood mononuclear cells (PBMCs; IC<sub>50</sub>s = 1.3 and 0.2 nM, respectively). Cabotegravir (50 mg/kg) is protective against simian/human immunodeficiency virus (SHIV) infection in macaques when administered 1 week prior to viral challenge.<sup>2</sup>

# References

- 1. Johns, B.A., Kawasuji, T., Weatherhead, J.G., et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J. Med. Chem. 56(14), 5901-5916 (2013).
- 2. Andrews, C.D., Spreen, W.R., Mohri, H., et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343(6175), 1151-1154 (2014).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

## SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/26/2023

# CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM